The polyamine metabolic pathway represents an attractive and novel target for chemotherapeutic intervention in the treatment of neoplastic disease. Interference with the pathway generally leads to a decrease in cellular growth rate, but in some specific instance results in phenotype- specific cytotoxicity. We have developed a number of synthetic routes that provide a pathway to a wide variety of novel unsymmetrically substituted polyamine analogues, many with unique biochemical activities. Forty-three new analogues have been synthesized to date and examined for their anti proliferative activity with the goal of elucidating their mechanism of action. The preliminary results demonstrate major findings provided by the study of these unique analogues. 1) The production of H2O2 produced as a result of analogue induced polyamine catabolism can play a significant role in the phenotype-specific cytotoxic response to some of the most promising analogues; 2) The cytotoxicity produced by the analogues results through caspase-dependent and - independent programmed cell death pathways; 3) A completely novel mechanisms of activity for polyamine analogue have been discovered, specifically the abilities to produced a G2/M block, alter tubulin polymerization and act as spindle poisons; 4) The study of these unique analogues has led to the discovery that the natural polyamines may have the important function of acting as free radical scavengers in protecting chromatin from reactive oxygen species attack. Based on these exciting preliminary results from the major goals of the studies detained in this application are to expand upon the above finding and to perform detailed structure analyses to aid in the production of more effective anti- neoplastic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA085509-03
Application #
6514412
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2000-03-01
Project End
2005-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
3
Fiscal Year
2002
Total Cost
$246,600
Indirect Cost
Name
Wayne State University
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Silva, T M; Oredsson, S; Persson, L et al. (2012) Novel Pt(II) and Pd(II) complexes with polyamine analogues: synthesis and vibrational analysis. J Inorg Biochem 108:1-7
Woster, Patrick M (2011) Use of polyamine derivatives as selective histone deacetylase inhibitors. Methods Mol Biol 720:475-91
Uimari, Anne; Keinanen, Tuomo A; Karppinen, Anne et al. (2009) Spermine analogue-regulated expression of spermidine/spermine N1-acetyltransferase and its effects on depletion of intracellular polyamine pools in mouse fetal fibroblasts. Biochem J 422:101-9
Bacchi, Cyrus J; Yarlett, Nigel; Faciane, Evangeline et al. (2009) Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi. Antimicrob Agents Chemother 53:2599-604
Casero Jr, Robert A; Woster, Patrick M (2009) Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 52:4551-73
Susick, Laura; Senanayake, Thulani; Veluthakal, Rajakrishnan et al. (2009) A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells. J Cell Mol Med 13:1877-85
Huang, Yi; Stewart, Tracy Murray; Wu, Yu et al. (2009) Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 15:7217-28
Huang, Yi; Marton, Laurence J; Woster, Patrick M et al. (2009) Polyamine analogues targeting epigenetic gene regulation. Essays Biochem 46:95-110
Senanayake, M D Thulani; Amunugama, Hemali; Boncher, Tracey D et al. (2009) Design of polyamine-based therapeutic agents: new targets and new directions. Essays Biochem 46:77-94
Basu, Hirak S; Thompson, Todd A; Church, Dawn R et al. (2009) A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 69:7689-95

Showing the most recent 10 out of 22 publications